Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218630 | 0.95 | EPHX2 (0.67) | EPHX2NOD1CA2CA4FAAH | |
| SCHEMBL7218627 | 0.95 | EPHX2 (0.67) | EPHX2NOD1CA2CA4FAAH | |
| SCHEMBL8005686 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL15650880 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL872338 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL25188341 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL17097126 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL1713210 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 | |
| SCHEMBL20552606 | 0.93 | EPHX2 (0.65) | EPHX2NOD1CA2CA4FAAH | |
| SCHEMBL8019819 | 0.93 | EPHX2 (0.69) | EPHX2NOD1FAAHMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | EPHX2 1062/4885NOD1 1456/4885CA2 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.